PALO ALTO, Calif., May 19, 2014 (GLOBE NEWSWIRE) -- The PAWS Pet Company, Inc. (OTCQB:PAWS), announces that its First Quarter 10Q filing will not be filed on time due to the complexity and extreme amount accounting work required by its recent merger.
Having the 10Q come on the heels of the 2013 10K we filed last month has created an enormous amount of work. Our financial team has worked around the clock to get the 10Q done and we are close. Unfortunately It will take a few more days." said Dan Wiesel, CEO of The PAWS Pet Company. "Going forward, these difficulties will be behind us and we will strive to file on time in the future."
On a positive note, our paperwork for the name change to PraXsyn has been submitted to FINRA, and shortly we will also begin to work on our symbol change.
Also, we have taken out more space adjacent to our facilities, and we have doubled our pharmacy work area to accommodate the increased volume of prescriptions we are filling.
Our goal at PraXsyn to is provide medical practitioners with products and services to help them help their patients. Our Mesa Pharmacy division currently provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek.
About PraXsyn, Inc.
PraXsyn, Inc. is dedicated to providing medical practitioners with medications and services for their patients. We currently formulate transdermal creams in our compounding pharmacy, Mesa Pharmacy. These are geared to patients suffering from long-term pain associated with work place related injuries. In the near future, we will be instituting our Point of Care/In-Office Dispensing Program, and our In-Office Toxicology Testing. As the medical industry changes, PraXsyn will be there to provide different delivery systems.
For additional information go to www.praxsyn.com.
Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.